<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867267</url>
  </required_header>
  <id_info>
    <org_study_id>ZDX-2015-11</org_study_id>
    <nct_id>NCT02867267</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Ta1 for Sepsis</brief_title>
  <acronym>TESTS</acronym>
  <official_title>The Efficacy and Safety of Thymosin Alpha 1 for Sepsis: a Multicenter , Double-Blinded, Randomized and Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether thymalfasin is safe and effective in&#xD;
      patients who have sepsis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous study reported that the 7-day treatment of Ta 1 demonstrated positive active&#xD;
      effect as to the 28-day all-cause mortality and the augmentation of mHLA-DR (monocyte Human&#xD;
      Leukocyte Antigen DR) at the secondary endpoint. Therefore, we intend to verify this finding&#xD;
      through a randomized, double-blind and placebo-controlled clinical trial and the trail will&#xD;
      include subjects with impaired immunologic functions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">January 22, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of emerging infection within 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>from initial injection on day 0 to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day clearance rate of pathogenic microorganism</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stays</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stays</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day re-hospitalization rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of SOFA score at screening, end of CTM, days 7 (if applicable), day 14 and day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRRT-free days within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive agents-free days within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day SF-36 QOL scale</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variance of the count of monocyte human lymphocyte antigens-DR (mHLA-DR) at days 7, 14 and 28 compared with the baseline at screening</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The count of Treg cells at screening and days 7</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1106</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>thymosin alpha 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin alpha 1</intervention_name>
    <description>Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.</description>
    <arm_group_label>thymosin alpha 1</arm_group_label>
    <other_name>thymalfasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤85;&#xD;
&#xD;
          2. Signed informed consent signed;&#xD;
&#xD;
          3. Diagnosed as a sepsis according to the sepsis diagnosis criteria in &quot;Surviving Sepsis&#xD;
             Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016&quot;:&#xD;
             at least one acute severe organ failure related to sepsis, and total SOFA scores ≥2;&#xD;
&#xD;
          4. Infected focus are confirmed or suspected and satisfy at least one of the followings:&#xD;
&#xD;
               1. pathogenic microbes grow in blood and at aseptic locations&#xD;
&#xD;
               2. presence of abscess or partially-infected tissues&#xD;
&#xD;
               3. suspected infection identified by at least one of the following evidences:&#xD;
&#xD;
                    -  leukocytes at normal aseptic locations&#xD;
&#xD;
                    -  organic perforation (confirmed by imaging evidence, examination result or&#xD;
                       intestinal content leak during drainage)&#xD;
&#xD;
                    -  Imaging evidence of pneumonia accompanied by purulent secretion&#xD;
&#xD;
                    -  Related syndromes with high infection risk (cholangitis for example)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of organ or bone marrow transplantation;&#xD;
&#xD;
          2. Active connective tissue diseases (such as rheumatoid diseases, systemic lupus&#xD;
             erythematosus) and glomerulonephritis;&#xD;
&#xD;
          3. Under pregnancy or in suckling period;&#xD;
&#xD;
          4. Presence of hematologic malignancies;&#xD;
&#xD;
          5. The patient has received radiotherapy or chemotherapy within the past 30 days;&#xD;
&#xD;
          6. The patient is inclined to stop or cancel the artificial intervention for sustaining&#xD;
             life, in other words, has abandoned treatment;&#xD;
&#xD;
          7. The patient has in the past 30 days received immunosuppressive drugs (tripterygium&#xD;
             wilfordii, CellCept, cyclophosphamide, FK506, etc.) or received continuous treatment&#xD;
             with prednisolone &gt;10 mg/day (or the same dose of other hormones);&#xD;
&#xD;
          8. The patient could die of an underlying disease within 28 days or is in end-stage;&#xD;
&#xD;
          9. The patient has undergone CPR in the 72 hours before signing the informed consent and&#xD;
             the neuromechanism has not fully recovered (GCS score ≤ 8);&#xD;
&#xD;
         10. The patient has in the past 30 days used thymosin or undergone certain clinical drug&#xD;
             or instrument trials which could affect immunity (such as Xuebijing, ulinastatin and&#xD;
             CRRT);&#xD;
&#xD;
         11. The patient has a medical history of allergy or intolerance to thymalfasin;&#xD;
&#xD;
         12. The source of infection cannot be contained, for example: infections that cannot be&#xD;
             handled during surgical operations and drainage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guan Xiangdong, M. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingyuan People's Hospital</name>
      <address>
        <city>Qingyuan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Commend</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi 'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 Jan 17;17(1):R8. doi: 10.1186/cc11932.</citation>
    <PMID>23327199</PMID>
  </results_reference>
  <results_reference>
    <citation>Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E, Puccetti P. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007 Sep;1112:326-38. Epub 2007 May 10. Review.</citation>
    <PMID>17495242</PMID>
  </results_reference>
  <results_reference>
    <citation>Romani L, Moretti S, Fallarino F, Bozza S, Ruggeri L, Casagrande A, Aversa F, Bistoni F, Velardi A, Garaci E. Jack of all trades: thymosin α1 and its pleiotropy. Ann N Y Acad Sci. 2012 Oct;1269:1-6. doi: 10.1111/j.1749-6632.2012.06716.x. Review.</citation>
    <PMID>23045964</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Li W, Niu C, Pan L, Li N, Li J. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011 Jun;34(3):198-202. doi: 10.1007/s10753-010-9224-1. Erratum in: Inflammation. 2011 Jun;34(3):222-3.</citation>
    <PMID>20549321</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wu Jianfeng</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>thymosin alpha 1; thymalfasin; sepsis; immunodepression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

